These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review. Miskovic R; Radovic S; Arandjelovic S; Plavsic A; Reljic V; Peric J; Brkovic V; Stojanovic M Rheumatol Int; 2024 Nov; 44(11):2621-2635. PubMed ID: 39284920 [TBL] [Abstract][Full Text] [Related]
4. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States. Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942 [TBL] [Abstract][Full Text] [Related]
5. Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021. See I; Lale A; Marquez P; Streiff MB; Wheeler AP; Tepper NK; Woo EJ; Broder KR; Edwards KM; Gallego R; Geller AI; Jackson KA; Sharma S; Talaat KR; Walter EB; Akpan IJ; Ortel TL; Urrutia VC; Walker SC; Yui JC; Shimabukuro TT; Mba-Jonas A; Su JR; Shay DK Ann Intern Med; 2022 Apr; 175(4):513-522. PubMed ID: 35038274 [TBL] [Abstract][Full Text] [Related]
6. Cutaneous leukocytoclastic vasculitis after second dose of mRNA COVID-19 vaccine. Simon SC; Olsavszky V Dermatol Online J; 2022 Oct; 28(5):. PubMed ID: 36809133 [TBL] [Abstract][Full Text] [Related]
7. SEVERE LEUKOCYTOCLASTIC VASCULITIS AFTER COVID-19 VACCINATION - CAUSE OR COINCIDENCE? CASE REPORT AND LITERATURE REVIEW. Wollina U; Schönlebe J; Kodim A; Hansel G Georgian Med News; 2022 Mar; (324):134-139. PubMed ID: 35417874 [TBL] [Abstract][Full Text] [Related]
8. A Case of Leukocytoclastic Vasculitis Following SARS-COV-2 Vaccination. Ball-Burack MR; Kosowsky JM J Emerg Med; 2022 Aug; 63(2):e62-e65. PubMed ID: 35690533 [TBL] [Abstract][Full Text] [Related]
9. Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S. Struyf F; Hardt K; Van Rampelbergh R; Shukarev G; Inamdar A; Ruiz-Guiñazú J; van Paassen V; Anaya-Velarde L; Diba C; Ceuppens M; Cardenas V; Soff GA; Pragalos A; Sadoff J; Douoguih M Vaccine; 2023 Aug; 41(37):5351-5359. PubMed ID: 37517912 [TBL] [Abstract][Full Text] [Related]
10. Guillain-Barré Syndrome After Ad26.COV2.S Vaccination. Thant HL; Morgan R; Paese MM; Persaud T; Diaz J; Hurtado L Am J Case Rep; 2022 Feb; 23():e935275. PubMed ID: 35157644 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM; N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226 [TBL] [Abstract][Full Text] [Related]
12. Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil. Mouta Nunes de Oliveira P; Mendes-de-Almeida DP; Bertollo Gomes Porto V; Crespo Cordeiro C; Vitiello Teixeira G; Saraiva Pedro R; Roberto Gomes Takey P; Kegele Lignani L; Reis Xavier J; Cardoso Doria da Gama V; Amorim Filho L; Emoingt Furtado B; Santa Maria A; Dahrug Barros T; Neves Waite Freitas L; Dos Santos Pereira T; Lima Abreu D; Bernardes Ramos M; Gabe C; Arnold D; William Smith J; Nazy I; Lourdes de Sousa Maia M; Vaccine; 2022 Aug; 40(33):4788-4795. PubMed ID: 35779962 [TBL] [Abstract][Full Text] [Related]
13. Vaccine-induced massive pulmonary embolism and thrombocytopenia following a single dose of Janssen Ad26.COV2.S vaccination. Curcio R; Gandolfo V; Alcidi R; Giacomino L; Campanella T; Casarola G; Rossi R; Chiatti L; D'Abbondanza M; Commissari R; Gresele P; Pucci G; Vaudo G Int J Infect Dis; 2022 Mar; 116():154-156. PubMed ID: 34986404 [TBL] [Abstract][Full Text] [Related]
14. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. Woo EJ; Mba-Jonas A; Dimova RB; Alimchandani M; Zinderman CE; Nair N JAMA; 2021 Oct; 326(16):1606-1613. PubMed ID: 34617967 [TBL] [Abstract][Full Text] [Related]
15. Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi: Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021. Makonokaya L; Kapanda L; Woelk GB; Chauma-Mwale A; Kalitera LU; Nkhoma H; Zimba S; Chamanga R; Golowa C; Machekano R; Maphosa T Int J Environ Res Public Health; 2023 Nov; 20(23):. PubMed ID: 38063553 [TBL] [Abstract][Full Text] [Related]
16. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. See I; Su JR; Lale A; Woo EJ; Guh AY; Shimabukuro TT; Streiff MB; Rao AK; Wheeler AP; Beavers SF; Durbin AP; Edwards K; Miller E; Harrington TA; Mba-Jonas A; Nair N; Nguyen DT; Talaat KR; Urrutia VC; Walker SC; Creech CB; Clark TA; DeStefano F; Broder KR JAMA; 2021 Jun; 325(24):2448-2456. PubMed ID: 33929487 [TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 vaccination-induced cutaneous vasculitis: Report of two new cases and literature review. Abdelmaksoud A; Wollina U; Temiz SA; Hasan A Dermatol Ther; 2022 Jun; 35(6):e15458. PubMed ID: 35306713 [TBL] [Abstract][Full Text] [Related]
19. [Leukocytoclastic vasculitis and acute renal failure following inactivated SARS-CoV-2 vaccine]. Missoum S; Lahmar M; Khellaf G Nephrol Ther; 2022 Jul; 18(4):287-290. PubMed ID: 35074300 [TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection. Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY Front Immunol; 2023; 14():1131229. PubMed ID: 36960070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]